Epigenetics and eye health II – Macular degeneration

At first you have a little trouble focusing, but you chalk it up to age. But then something strange happens – a hole appears in your field of vision. And strangely, it’s always right where you’re trying to focus, while the surrounding objects remain clear. You have trouble reading, watching TV, you can’t recognize your friends’ faces… This is how macular degeneration, a serious eye disease, manifests itself, which we’ll look at in the second part of our mini-series on eye health from an epigenetic perspective.
The human eye is a very complex structure and therefore a high number of genes are involved in its development and function – about 90% of those contained in our DNA. In order for everything to work as it should, the necessary genes must be switched on so that the organism can make proteins according to them. However, due to the environment, diet, lifestyle, and aging, a number of so-called epigenetic reactions take place in our bodies that negatively affect the activity of the genes in our DNA, which is reflected in an increased risk of eye diseases. In the first part of our miniseries we looked at cataracts from this perspective(https://www.epivyziva.cz/epigenetika-a-zdravi-oci-i-prevence-sedeho-zakalu/), today we will focus on macular degeneration.
The latter is one of the diseases in which epigenetic reactions play a major role. In fact, it is closely linked to ageing – its full name is “age-related macular degeneration”. The number of negative epigenetic marks on our genes generally increases with age, and those responsible for eye function are no exception. Others increase, for example, in connection with poor nutrition, lack of exercise, exposure to UV radiation, environmental toxins, smoking, etc.
What is macular degeneration?
Macular degeneration is a degenerative disease of the retina, which unfortunately manifests itself mostly in the area of the macula. This is an area with a high density of cones, i.e. light-sensitive cells, where the rays reflected from the objects we focus on fall. This is also why the ability to see in the centre of the field of vision is first impaired, while peripheral vision is preserved.
Often, people do not notice the development of the disease for a long time, attributing the impaired ability to focus to, for example, old-age hyperopia. In addition, if vision deteriorates in only one eye, the brain can “compensate” and vision deteriorates only slightly.
Macular degeneration comes in two forms. The most common (about 85% of cases) is the so-called dry form, which consists of a loss of retinal cells. It develops relatively slowly, but the treatment options are very limited – basically they consist of carotenoid administration. On the other hand, the wet form, which consists of blood vessels growing into places where they do not belong, is insidious in that it progresses very quickly – significant deterioration of vision (or even blindness) occurs within weeks or months. However, if caught early, it is treatable.
Is it free radicals?
Why are carotenoids given in the dry form of macular degeneration? The main reason is that they are powerful antioxidants that work effectively in the eye area. Damage to the structures of the eye by free radicals is a major contributor to macular degeneration (MD). But equally important is the influence of epigenetic reactions on gene activity. Scientific research has already demonstrated the existence of a number of epigenetic mechanisms and more will surely follow.
Moreover, even a lack of protection against free radicals may have an epigenetic background. In fact, in people suffering from the disease, scientists have discovered reduced levels of the enzymes glutathione S-transferases (PI, mu1 and mu5), which serve as scavengers of harmful oxygen free radicals. A deficiency of these enzymes thus leads to increased oxidative damage to the retina. At the same time, studies in people with MD have also shown increased methylation of the promoters of the genes by which these enzymes are produced. Methylation is one of the three basic epigenetic reactions – if it is increased in the area of the so-called promoters (the parts of DNA that start reading a certain gene), the activity of this gene decreases, and it may even be switched off completely.
However, other epigenetic links have also been demonstrated:
- Patients with MD have increased methylation in the region of the gene for interleukin C receptor 17, a substance important for cell signalling.
- People with MD have increased methylation of the genes that make clusterin and vitronectin in the body. These proteins prevent cells from breaking down, and if there is a deficiency of them in the body, it exacerbates the rate of inflammatory processes and can also lead to the development of MD.
- Another epigenetic reaction, histone acetylation, also plays a role. Histones are the proteins on which DNA strands are “wound”. Genes in a particular region can only be read if their histones are acetylated. If they are deacetylated, which is done by enzymes called deacetylases, the genes are switched off. But if we can reduce the amount of deacetylases, we increase the activity of genes that protect retinal cells from damage due to lack of oxygen, for example (this is particularly common in the wet form of MD).
- Differences in the production of so-called microRNAs – small chains of ribonucleic acids that can also block gene transcription – have also been shown. Some of them (for example microRNA 23) can increase the protection of cells against free radical damage, while others are involved in the regulation of inflammatory processes.
- In addition, some microRNAs are involved in reduced levels of the so-called CHF factor, which causes inflammatory degeneration of nerve cells. Interestingly, this mechanism is found not only in MD but also in Alzheimer’s disease.
What can help?
In light of the growing knowledge about the epigenetic causes of macular degeneration, scientists are already developing drugs that will work on the epigenetic principle (for example, the possibility of using microRNA 21 seems promising). At the same time, it is worthwhile to try to influence the level of epigenetic reactions in our body by diet and other lifestyle modifications.
In particular, we should focus on factors that affect the rate of overall ageing, because the rate of ageing is determined by the presence of negative epigenetic changes in our DNA.
- A healthy diet with plenty of antioxidants is important – a positive effect has been shown especially for the carotenoids lutein and zeaxanthin, which are found, for example, in egg yolks, corn, apricots, blueberries, walnuts, grape wine, curcurrants and other foods.
- The beneficial effect of anthocyanins (a dye found in berries) has also been confirmed.
- Research has also revealed a significant protective effect of regular fish consumption.
- Getting enough exercise is important.
- On the other hand, smoking (its influence on the development of MD has been demonstrated in studies on twins), excessive alcohol consumption and environmental toxins have negative effects.
Dietary supplements
Nutrients and herbs that combine antioxidant and epigenetic effects can also be of great service to us. If taken in high concentrations (i.e. in the form of dietary supplements), they can make a significant contribution not only to stopping macular degeneration, but also to healing the whole body.
Astaxanthin – this is a dye from the carotenoid family with a positive effect on the health of the whole eye. It has significant antioxidant potential and effectively reduces the level of free radicals in the eye area, but it also has epigenetic effects. For example, it influences the production of endothelial factors involved in blood vessel growth.
Omega-3s – consumption of two in particular, EPA and DHA, has been linked to the risk of macular degeneration. DHA in particular plays an important role in maintaining normal vision in general. In addition, it is used in the body to produce neuroprotectin D1, a substance with a strong protective effect on nerve cells, and is also important for maintaining optimal permeability and thickness of the cell membranes of rods and cones and for activating specific proteins in the retina.
Resveratrol, a powerful antioxidant with anti-inflammatory effects, regulates the activity of several genes related to the development of MD, protects retinal cells, influences the production of endothelial factor, which regulates the formation of new blood vessels (this is particularly important in the wet form of MD), and has an overall effect on slowing aging by influencing all the basic epigenetic reactions.
Rosemary – the extract of this herb has a significant antioxidant, anti-inflammatory and also epigenetic effect. For example, it very effectively protects retinal cells from damage (this is mainly due to the carnosol and carnosolic acid it contains).
- AREDS report no. 8. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Ophthalmology 2001; 119: 1417–1436.
- Ates O, Azizi S, Alp HH, Kiziltunk A, Beydemir S, Cinici E et al. Decreased serum paraoxonase 1 activity and increased serum homocysteine and malondialdehyde levels in age-related macular degeneration. Tohoku J Exp Med 2009; 217: 17–22.
- Friedman DS, O’Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT et al. Prevalence of age related macular degeneration in the United States. Arch Ophthalmol 2004; 122: 564–572.
- Buch H, Vinding T, la Cour M, Jensen GB, Prause JU, Nielsen NV. Risk factors for age-related maculopathy in a 14-year follow-up study: the Copenhagen City Eye Study. Acta Ophthalmol Scand 2005; 83: 409–418.
- Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 2001; 108: 697–704.
- Frederick JM, Rayborn ME, Laties AM, Lam DM, Hollyfield JG. Dopaminergic neurons in the human retina. J Comp Neurol 1982; 210: 65–79.
- Hyman LG, Lilienfeld AM, Ferris FL III, Fine SL. Senile macular degeneration: a case–control study. Am J Epidemiol 1983; 118: 213–227.
- Hunter A, Spechler PA, Cwanger A, Song Y, Zhang Z, Ying GS et al. dna methylation is associated with altered gene expression in AMD. IOVS 2012; 53: 2089–2105.
- Wei L, Liu B, Tuo J, Shen D, Chen P, Li Z et al. Hypomethylation of IL17RC promoter associates with age related macular degeneration. Cell Rep 2012; 1151–1158.
- Oliver VF, Franchina M, Jaffe AE, Branham KE, Othman M, Heckenlively JR et al. Hypomethylation of the IL17RC promoter in peripheral blood leukocytes is not a hallmark of age-related macular degeneration. Cell Rep 2013; 5: 1527–1535.
- Crabb JW, Miyagi M, Gu X, Shadrach K, West KA, Sakaguchi H et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci USA 2002; 99: 14619–14621.
- Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002; 134: 411–431.
- Jenne DE, Lowin B, Peitsch MC, Bottcher A, Schmitz G, Tschopp J. Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. J Biol Chem 1991; 266: 11030–11036.
- Suuronen T, Nuutinen T, Ryhänen T, Kaarniranta K, Salminen A. Epigenetic regulation of clusterin/apolipoprotein J expression in retinal pigment epithelial cells. Biochem Biophys Res Commun 2007; 357: 397–401.
- Goettlicher M, Minucci S, Zhu P, Krámer OH, Schimpf A, Giavara S et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969–6978.
- Sabatel C, Malvaux L, Bovy N, Deroanne C, Lambert V, Gonzalez ML et al. MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. PLoS One 2011; 6: e16979.
- Shen J, Yang X, Xie B, Chen Y, Swaim M, Hackett SF et al. MicroRNAs regulate ocular neovascularization. Mol Ther 2008; 16: 1208–1216.
- Cheng Y, Liu X, Zhang S, Lin Y, Yang J, Zhang C. MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4. J Mol Cell Cardiol 2009; 47: 5–14.
- Tang Y, Zheng J, Sun Y, Wu Z, Liu Z, Huang G. MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bcl-2. Int Heart J 2009; 50: 377–387.
- Winkler BS, Boulton ME, Gottsch JD, Sternberg P. Oxidative damage and age-related macular degeneration. Mol Vis 1999; 5: 32.
- Hollyfield JG. Age-related macular degeneration: the molecular link between oxidative damage, tissue-specific inflammation and outer retinal disease: the Proctor lecture. Invest Ophthalmol Vis Sci 2010; 51: 1275–1281. | Article | PubMed |
- Cai J, Wu M, Nelson KC, Sternberg P Jr, Jones DP. Oxidant-induced apoptosis in cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1999; 40: 959–966.
- Kim MH, Chung J, Yang JW, Chung SM, Kwag NH, Yoo JS. Hydrogen peroxide-induced cell death in a human retinal pigment epithelial cell line, ARPE-19. Korean J Ophthalmol 2003; 17: 19–28.
- Lin H, Qian J, Castillo AC, Long B, Keyes KT, Chen G et al. Effect of miR-23 on oxidant-induced injury in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2011; 52: 6308–6314.
- Lukiw WJ, Surjyadipta B, Dua P, Alexandrov PN. Common micro RNAs (miRNAs) target complement factor H (CFH) regulation in Alzheimer’s disease (AD) and in agerelated macular degeneration (AMD). Int J Biochem Mol Biol 2012; 3: 105–116.
- Hirotaka Hashimoto, Kiyomi Arai, Shimmin Hayashi, Hiroyuki Okamoto, Jiro Takahashi, and Makoto Chikuda. The effect of astaxanthin on vascular endothelial growth factor (VEGF) levels and peroxidation reactions in the aqueous humor. J Clin Biochem Nutr. 2016 Jul; 59(1): 10–15.
- Seddon JM, George S, Rosner B. Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: the US Twin Study of Age-Related Macular Degeneration. Arch Ophthalmol. 2006 Jul;124(7):995-1001.
- Rahman MM, Ichiyanagi T, Komiyama T, Hatano Y & Konishi T (2006): Superoxide radical‐ and peroxynitrite‐scavenging activity of anthocyanins; structure‐activity relationship and their synergism. Free Radic Res 40: 993–1002.
- Gordon WC & Bazan NG (2013): Mediator lipidomics in ophthalmology: targets for modulation in inflammation, neuroprotection and nerve regeneration. Curr Eye Res 38: 995–1005.
- SanGiovanni JP & Chew EY (2005): The role of omega‐3 long‐chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res 24: 87–138.
- Querques G & Souied EH (2014): The role of omega‐3 and micronutrients in age‐related macular degeneration. Surv Ophthalmol 59: 532–539.
- Obisesan TO, Hirsch R, Kosoko O, Carlson L & Parrott M (1998): Moderate wine consumption is associated with decreased odds of developing age‐related macular degeneration in NHANES‐1. J Am Geriatr Soc 46: 1–7.
- Balaiya S, Murthy RK & Chalam KV (2013): Resveratrol inhibits proliferation of hypoxic choroidal vascular endothelial cells. Mol Vis 19: 2385–2392.
- King RE, Kent KD & Bomser JA (2005): Resveratrol reduces oxidation and proliferation of human retinal pigment epithelial cells via extracellular signal‐regulated kinase inhibition. Chem Biol Interact 151: 143–149.
- Shindler KS, Ventura E, Dutt M, Elliott P, Fitzgerald DC & Rostami A (2010): Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J Neuroophthalmol 30: 328–339.
- T. Rezaie, S. R. McKercher, K. Kosaka, M. Seki, L. Wheeler, V. Viswanath, T. Chun, R. Joshi, M. Valencia, S. Sasaki, T. Tozawa, T. Satoh, S. A. Lipton. Protective effect of carnosic acid, a pro-electrophilic compound, in models of oxidative stress and light-induced retinal degeneration. Investigative Ophthalmology & Visual Science, 2012;





2 Comments
Hello,I would like to ask if epigenetics can still affect (stop) the already advanced macular degeneration.My mother can only see peripherally, she can no longer read anything, the condition is slowly deteriorating.If so, how to use the products (you mention here Astaxanthin, Omega-3, Resveratrol and Rosemary)? Should she take them gradually or all at once and how to dose? Thank you for your answer.Hello Alena.
Hello,
It is certainly possible to achieve a significant slowing down of the progression of the disease, but stopping or even a slight improvement cannot be ruled out (no significant improvement is possible). Omega-3s are essential. I recommend buying the oil (not the capsules) and feel free to give mom a drink straight from the bottle. People who really need it often just like the oil and intuitively dose it as needed. It is also suitable for long-term use. For this you can give astaxanthin – at first, take 3-4 capsules, after three weeks reduce to 1-2 capsules and after two months take a break. A combination of omega-3 with rosemary is also suitable, so if she won’t take astaxanthin, you can continue with rosemary. Give the resveratrol separately, and if mom likes wine, pour her a glass of red with it, it will be better absorbed.